Search Results

You are looking at 131 - 140 of 569 items for :

  • Refine by Access: All x
Clear All
Full access

Belzutifan in a Patient With VHL-Associated Metastatic Pancreatic Neuroendocrine Tumor

Eleonora Pelle, Taymeyah Al-Toubah, Brian Morse, and Jonathan Strosberg

was 49%. 7 , 12 Incidentally, 22 patients on this trial had localized pNETs, 20 (91%) of whom experienced objective radiographic response of their pancreatic tumors. The most common adverse events were anemia (experienced among 90%) and fatigue (66

Full access

Near Complete Response to Trametinib Treatment in Histiocytic Sarcoma Harboring a Somatic KRAS Mutation

Boyu Hu, Jay L. Patel, Randa Tao, Richard B. Cannon, Marcus Monroe, and Gaurav Goyal

lesion and most of the cervical lymph nodes. After 7 months of therapy, trametinib dose was decreased to 1.5 mg daily due to the patient experiencing grade 2 fatigue, peripheral edema, and acneiform rash. At 1 year of therapy with trametinib, the patient

Full access

The Changing Paradigm of Treating Pancreatic Neuroendocrine Tumors

Renuka Iyer and Kaunteya Reddy

in the placebo group. The most frequent treatment-related adverse events were stomatitis, rash, fatigue, diarrhea, and respiratory infections. Everolimus benefit was due to tumor stabilization in most cases. Promising phase II data prompted another

Full access

Updates on the Management of Immunotherapy-Related Toxicities

Presented by: Marianne Davies, Jordan McPherson, and John A. Thompson

. Common toxicities include fatigue, pruritus, rash, nausea, and vomiting, but continuous monitoring for side effects is necessary throughout treatment, because specific irAEs may affect any organ system, are highly unpredictable, and vary in their timing

Full access

Another New Beginning

Margaret Tempero

, I will advocate for fair drug pricing and adequate coverage of oral cancer drugs for seniors. I will stop saying “yes” to so many opportunities. Burnout and fatigue are real and impair our ability to fully express the compassion we have for

Full access

Being Closer to Normal

Margaret Tempero

quite a while, and travel restrictions remain in effect, which is fine, because all the big professional meetings we enjoy each spring and summer are being held virtually for the second year in a row. I do have mask fatigue, though. I don’t find

Full access

Adverse Events Reported by Patients With Cancer After Administration of a 2-Dose mRNA COVID-19 Vaccine

Rebecca M. Shulman, David S. Weinberg, Eric A. Ross, Karen Ruth, Glenn F. Rall, Anthony J. Olszanski, James Helstrom, Michael J. Hall, Julia Judd, David Y.T. Chen, Robert G. Uzzo, Timothy P. Dougherty, Riley Williams, Daniel M. Geynisman, Carolyn Y. Fang, Richard I. Fisher, Marshall Strother, Erica Huelsmann, Sunil Adige, Peter D. Whooley, Kevin Zarrabi, Brinda Gupta, Pritish Iyer, Melissa McShane, Hilario Yankey, Charles T. Lee, Nina Burbure, Lauren E. Laderman, Julie Giurintano, Samuel Reiss, and Eric M. Horwitz

fatigue, joint pain, fever, chills, headache, and nausea. Allergic reactions were rare after both dose 1 (6/1,752) and dose 2 (9/1,261). Postvaccination symptoms for all patients were more likely to be reported by women than by men (77.8% vs 65.5%; P

Full access

Impact of Muscle Measures on Outcome in Patients Receiving Endocrine Therapy for Metastatic Breast Cancer: Analysis of ECOG-ACRIN E2112

Tarah J. Ballinger, Helga S. Marques, Gloria Xue, Richard Hoffman, Constantine Gatsonis, Fengmin Zhao, Kathy D. Miller, Joseph Sparano, and Roisin M. Connolly

-G (Functional Assessment of Cancer Therapy—General), Patient-Reported Outcomes Measurement Information System (PROMIS)–Fatigue, and Patient-Reported Outcomes version of the CTCAE (PRO-CTCAE) muscle ache and joint pain obtained after three 28-day cycles of

Full access

NCCN News

REMS. The table below reflects a sample of drugs recently added that may be used for a supportive care indication (e.g., pain, cancer-related fatigue) in a patient with cancer. All the drugs listed require the provision of a medication guide detailing

Full access

Oncology Research Program

, but in the advanced setting can be very disabling and can impact quality of life (QOL) due to diarrhea, bowel obstructions, pain, weight loss, depression, and fatigue. Many of the abdominal symptoms are caused by the dense adhesions. Midgut carcinoids